MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat
Abstract Background Small cell lung cancer (SCLC) is an aggressive neuroendocrine cancer with an appalling overall survival of less than 5% (Zimmerman et al.J Thor Oncol 14:768-83, 2019).Patients typically respond to front line platinum-based doublet chemotherapy, Firewire but almost universally relapse with drug resistant disease.Elevated MYC expr